

Day: Tuesday Date: 7/6/2004 Time: 09:10:25

## **Inventor Name Search**

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name
Orson	Frank Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

## **Refine Search**

#### Search Results -

Term	Documents
(13 NOT 5).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	48
(L13 NOT L5 ).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	48

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Database:



Refine Search





Interrupt

#### **Search History**

DATE: Tuesday, July 06, 2004 Printable Copy Create Case

side by side	Query	<u>Hit</u> <u>Count</u>	Set Name result set
	PGPB, USPT, USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YI	ES;	
OP=AN		40	T 1 4
<u>L14</u>	L13 not L5	48	<u>L14</u>
<u>L13</u>	L12 and ((DNA adj vaccine) or (genetic adj immunization))	50	<u>L13</u>
L12	L11 and (DNA or plasmid or vector)	889	<u>L12</u>
<u>L11</u>	(conjugation or conjugate) same ((antibody or Ab) and (polycationic or polyethylenimine or polyimmine or polylysine or PEI))	1021	<u>L11</u>
L10	(Ab-PEI-DNA)	0	<u>L10</u>
L9	L7 and L3	1	<u>L9</u>
<u>L8</u>	L7 and L2	6	<u>L8</u>
<u>L7</u>	(Expression adj library) adj immunization	68	<u>L7</u>
L6	L5 and ((DNA adj vaccine) or (genetic adj immunization))	4	<u>L6</u>
<u>L5</u>	L2 and L3	43	<u>L5</u>

<u>L4</u>	L2 same L3	2	<u>L4</u>
<u>L3</u>	(polycationic or polyethylenimine or polyimmine or polylysine) same (conjugate)	1352	<u>L3</u>
<u>L2</u>	(aggregated or macroaggregated) same (protein or albumin or antibody)	5088	<u>L2</u>
<u>L1</u>	Orson-Frank-M\$.in.	1	<u>L1</u>

## END OF SEARCH HISTORY

```
Welcome to DialogClassic Web(tm)
Dialog level 04.11.00D
Last logoff: 01jul04 16:26:33
Logon file001 06jul04 11:25:52
          *** ANNOUNCEMENT ***
                   ***
--File 654 - US published applications from March 15, 2001 to the
present are now online. Please see HELP NEWS 654 for details.
--File 581 - The 2003 annual reload of Population Demographics is
complete. Please see Help News581 for details.
--File 990 - NewsRoom now contains February 2004 to current records.
File 992 - NewsRoom 2003 archive has been newly created and contains
records from January 2003. The oldest months's records roll out of
File 990 and into File 992 on the first weekend of each month.
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new
OneSearch category.
--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.
                   *** --SourceOne patents are now delivered to your email inbox
as PDF replacing TIFF delivery. See HELP SOURCE1 for more
information.
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
NEW FILES RELEASED
***MetalBase (File 36)
***AeroBase (File 104)
***DIOGENES: Adverse Drug Events Database (File 181)
***World News Connection (File 985)
***Dialog NewsRoom - 2003 Archive (File 992)
***TRADEMARKSCAN-Czech Republic (File 680)
***TRADEMARKSCAN-Hungary (File 681)
***TRADEMARKSCAN-Poland (File 682)
UPDATING RESUMED
RELOADED
***Toxfile (File 156)
***Medline (Files 154-155)
***Population Demographics - (File 581)
***CLAIMS Citation (Files 220-222)
REMOVED
     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>> of new databases, price changes, etc.
KWIC is set to 50.
HILIGHT set on as ' '
  * * * *
       1:ERIC 1966-2004/Jun 09
File
        (c) format only 2004 The Dialog Corporation
       Set Items Description
            ----
```

```
Cost is in DialUnits
B 155, 159, 5, 73
       06jul04 11:26:41 User259876 Session D646.1
                    0.178 DialUnits File1
            $0.62
     $0.62 Estimated cost File1
     $0.20 INTERNET
     $0.82 Estimated cost this search
     $0.82 Estimated total session cost 0.178 DialUnits
SYSTEM:OS - DIALOG OneSearch
  File 155:MEDLINE(R) 1966-2004/Jun W2
         (c) format only 2004 The Dialog Corp.
 *File 155: Medline has been reloaded. Accession numbers
have changed. Please see HELP NEWS 154 for details.
  File 159: Cancerlit 1975-2002/Oct
         (c) format only 2002 Dialog Corporation
 *File 159: Cancerlit ceases updating with immediate effect.
Please see HELP NEWS.
         5:Biosis Previews(R) 1969-2004/Jun W4
  File
         (c) 2004 BIOSIS
  File 73:EMBASE 1974-2004/Jun W4
         (c) 2004 Elsevier Science B.V.
      Set Items Description
          ----
 (AGGREGATED OR MACROAGGREGATED) (S) (PROTEIN OR ANTIBODY OR LIGAND OR ALBUMIN)
           37412 AGGREGATED
            1642 MACROAGGREGATED
         4188970 PROTEIN
         1308420 ANTIBODY
          310868 LIGAND
          279985 ALBUMIN
           15417 (AGGREGATED OR MACROAGGREGATED) (S) (PROTEIN OR ANTIBODY
      S1
                  OR LIGAND OR ALBUMIN)
S S1 (S) (DNA OR VECTOR OR GENE OR (GENETIC (W) IMMUNIZATION))
           15417 S1
         2574560 DNA
          284815 VECTOR
         2492137 GENE
         1577250 GENETIC
          202627 IMMUNIZATION
             952 GENETIC (W) IMMUNIZATION
            1278 S1 (S) (DNA OR VECTOR OR GENE OR (GENETIC (W)
      S2
                  IMMUNIZATION))
S S2 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENIMINE OR POLYIMMINE OR PEI)
            1278 S2
            2730 POLYCATIONIC
           10182 POLYLYSINE
               1 POLYETHELENIMINE
               0 POLYIMMINE
            3958 PEI
               7 S2 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENIMINE OR
      S3
                  POLYIMMINE OR PEI)
?
RD
 ...completed examining records
               3 RD (unique items)
T S4/3, K/ALL
               (Item 1 from file: 155)
   4/3,K/1
```

DIALOG(R) File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

12190474 PMID: 12526712

glycol-polyethylenimine/DNA shielded transferrin-polyethylene complexes for systemic tumor-targeted gene transfer.

Kursa Malgorzata; Walker Greg F; Roessler Vanessa; Ogris Manfred; Roedl Wolfgang; Kircheis Ralf; Wagner Ernst

Department for Biology-Biotechnology, Pharmaceutical Ludwig-Maximilians-Universitaet, Butenandtstrasse 5-13, D-81377 Muenchen, Germany.

Jan-Feb 2003, 14 (1) p222-31, Bioconjugate chemistry (United States)

Journal Code: 9010319 ISSN 1043-1802

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Tumor-targeting DNA complexes which can readily be generated by the mixing of stable components and freeze-thawed would be very advantageous for their subsequent application as medical products. Complexes were generated by the mixing of plasmid DNA , linear polyethylenimine (PEI22, 22 kDa) as the main DNA condensing agent, PEG- PEI (poly(ethylene glycol)-conjugated PEI ) for surface shielding, and Tf-PEG- PEI (transferrin-PEG- PEI ) to provide a ligand for receptor-mediated cell uptake. Within the shielding conjugates, PEG chains of varying size (5, 20, or 40 kDa) were conjugated with either linear PEI22 (22 kDa) or branched PEI25 (25 kDa). The three polymer components were mixed together at various ratios with DNA; particle size, surface charge, in vitro transfection activity, and systemic gene delivery to tumors was investigated. In general, increasing the proportion of shielding conjugate in the complex reduced surface charge, particle size, and in vitro transfection efficiency in transferrin receptor-rich K562 cells. The particle size or surface charge of the complexes containing the PEG- PEI conjugate did not significantly change after freeze-thawing, while complexes without the shielding conjugate aggregated . Complexes containing PEG- PEI conjugate efficiently transfected K562 cells after freeze-thawing. Furthermore the systemic application of freeze-thawed complexes exhibited in vivo tumor targeted expression. For complexes containing the luciferase reporter gene the highest expression was found in tumor tissue of mice. An optimum formulation for in vivo application, PEI22/Tf-PEG- PEI /PEI22-PEG5, for the tumor necrosis factor **DNA** encoding plasmid containing (TNF-alpha), inhibited tumor growth in three different murine tumor models. These new DNA complexes offer simplicity and convenience, with tumor targeting activity in vivo after freeze-thawing.

(Item 2 from file: 155) 4/3, K/2

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

PMID: 11741272 11586546

transfection particles: influence of ligands, DNA/polyethylenimine polymer size, and PEGylation on internalization and gene expression.

Ogris M; Steinlein P; Carotta S; Brunner S; Wagner E

Institute of Biochemistry, University of Vienna, Vienna, Austria.

manfred.ogris@cup.uni-muenchen.de

AAPS pharmSci electronic resource (United States) 2001, 3 (3) pE21, Journal Code: 100897065 ISSN 1522-1059

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

into DNA incorporated have been Receptor-binding ligands

/polyethylenimine ( PEI ) complexes to enhance cell binding and cellular internalization. This study characterizes receptor-mediated uptake of DNA / PEI complexes on a cellular basis. A novel assay based on flow cytometry total cell-associated between discriminating applied, extracellularly bound DNA complexes. Receptor-mediated uptake of ligand -containing DNA / PEI (molecular weight, 800 kd) complexes was found to occur quickly (within 1 hour), whereas unspecific uptake through adsorptive endocytosis is less efficient or requires extended periods to reach the same degree of internalization. Rapid, receptor-mediated internalization requires a small complex size; however, large, aggregated complexes show higher gene expression. Using PEI 25 kd conjugated to large proteins such as transferrin or antibodies, improper condensation with DNA leads to suboptimal uptake and gene expression, whereas partial replacement of - PEI with unconjugated [PEI] increases both uptake and transfection. In contrast, the 8 kd protein epidermal growth factor conjugated to PEI 25 kd properly condenses DNA and mediates specific uptake into human adenocarcinoma (KB) cells. Modification of the complex surface with appropriate amounts of poly(ethylene glycol) (PEG) does not block ligand -mediated internalization. A higher degree of PEGylation reduces the internalization of transferrin or antibody -containing complexes to a level similar to that of ligand -free complexes. In contrast, epidermal growth factor "mediated uptake is less effected by excessive PEGylation.

(Item 3 from file: 155) 4/3, K/3

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

PMID: 11437332 11347280

A small, synthetic peptide for gene delivery via the serpin-enzyme complex receptor.

Patel S; Zhang X; Collins L; Fabre J W

Department of Clinical Sciences, Guy's, King's and St Thomas' School of Medicine, King's College Hospital, London, UK.

journal of gene medicine (England) May-Jun 2001, 3 (3) p271-9,

ISSN 1099-498X Journal Code: 9815764

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

BACKGROUND: The serpin-enzyme complex receptor (SECR) has previously been successfully targeted for gene delivery using synthetic peptide ligands covalently linked in fluid phase to commercially available polylysine preparations (approximately 10-54kDa). The objective of the present study was to improve this approach by the use of small, bifunctional, and easily standardised synthetic peptides. METHODS: Two synthetic peptides designated 1 (PAT1) (K16 FNKPFVFLI) and PAT2 antitrypsin polylysine CSIPPEVKFNKPFVFLI) were evaluated for gene delivery to the HUH7 human hepatocyte cell line. The K16 moiety binds DNA electrostatically, while the FVFLM motif of human alphal-antitrypsin targets the SECR. RESULTS: Both PAT1 and PAT2 bind to and condense DNA into small particles as shown by laser scattering techniques. However, only PAT2 is effective for gene delivery, presumably on account of the greater distance between the K16 chain and the FVFLM motif. Gene delivery by PAT2/ DNA complexes is completely by free ligand be blocked chloroquine-dependent, can (CSIPPEVKFNKPFVFLI), and is highly efficient (e.g. approximately five-fold more effective than lipofectamine). At physiological salt concentrations, PAT2/ DNA complexes formed at 4 microg/ml DNA are approximately 350 nm in diameter and highly effective for gene transfer, but at 100 microg/ml DNA the complexes are aggregated (diameter > 4 microm) and inactive. CONCLUSIONS: A small (33 amino acid), bifunctional, synthetic peptide represents a highly efficient and readily standardised DNA vector for

```
the SECR. The effectiveness of this peptide depends on the distance of the
K16 moiety from the targeting ligand . High salt concentrations are not
                                             complexes.
required to form effective vector
                                       DNA
        Items
                Description
set
                (AGGREGATED OR MACROAGGREGATED) (S) (PROTEIN OR ANTIBODY OR
S1
        15417
              LIGAND OR ALBUMIN)
                S1 (S) (DNA OR VECTOR OR GENE OR (GENETIC (W) IMMUNIZATION-
S2
         1278
             ))
                S2 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENIMINE OR -
S3
             POLYIMMINE OR PEI)
                RD (unique items)
S4
?
S S2 AND (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR POLYIMMINE OR PEI)
            1278 S2
            2730 POLYCATIONIC
           10182 POLYLYSINE
                 POLYETHELENEIMINE
                0 POLYIMMINE
            3958 PEI
                  S2 AND (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE
              11
      S5
                   OR POLYIMMINE OR PEI)
?
RD S5
...completed examining records
                5 RD S5 (unique items)
      S6
S S6 NOT S3
                5
                  S6
                7
                  S3
                2 S6 NOT S3
      S7
2
T S7/3, K/ALL
               (Item 1 from file: 155)
  7/3, K/1
DIALOG(R) File 155: MEDLINE(R)
 (c) format only 2004 The Dialog Corp. All rts. reserv.
            PMID: 12749911
 12372498
 The phosphocholine and the polycation-binding sites on rabbit C-reactive
 protein are structurally and functionally distinct.
  Black Steven; Agrawal Alok; Samols David
  Department of Biochemistry, Case Western Reserve University, 10900 Euclid
 Avenue, Cleveland, OH 44106, USA.
                                                              p1045-54,
                                                                        ISSN
                                      Jun 2003,
                                                  39
                                                       (16)
  Molecular immunology (England)
             Journal Code: 7905289
 0161-5890
  Contract/Grant No.: AG02467; AG; NIA; AR40765; AR; NIAMS; DK07319; DK;
 NIDDK
   Document type: Journal Article
   Languages: ENGLISH
   Main Citation Owner: NLM
   Record type: Completed
   C-reactive protein (CRP) is an acute phase protein in humans and
 rabbits that has the ability to bind a number of biologically important
 ligands including phosphocholine (PCh), histones, and polycations. In addition to this recognition function, ligand -complexed or aggregated
     is capable of activating the classical complement pathway. We have
 generated two strains of transgenic mice in order to study CRP-binding to
 PCh and consequent complement activation. Based on crystallographic and
 mutagenesis studies in human CRP (huCRP), we mutated Phe66 and Glu81 in the
 rabbit CRP (rbCRP) gene and generated a strain of transgenic mice
             which expressed this variant form of rbCRP. We also mutated
 (F66Y/E81K),
```

Tyr175 in rbCRP to generate transgenic...

... rbCRP are distinct but possibly overlapping. The conformational changes in the Clq-binding site of CRP to activate complement depend on the nature of the ligand and on the location of the ligand -binding site.

Descriptors: C-Reactive Protein--chemistry--CH; \*C-Reactive Protein Classical; \*Phosphorylcholine \*Complement Pathway, --metabolism--ME; Polylysine --metabolism--ME --metabolism--ME;

Chemical Name: Cations; Histones; Polyamines; Polysaccharides, Bacterial; polycations; polysaccharide C-substance Bovine; Albumin, (Streptococcus); Phosphorylcholine; Polylysine; Lysine; Complement 1q; C-Reactive Protein

(Item 2 from file: 155) 7/3,K/2

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

PMID: 8146151 10029483

Utilization of modified surfactant-associated protein B for delivery of DNA to airway cells in culture.

Baatz J E; Bruno M D; Ciraolo P J; Glasser S W; Stripp B R; Smyth K L; Korfhagen T R

Pediatrics, Medical University of South Carolina, Department of Charleston 29425-3313.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Mar 29 1994, 91 (7) p2547-51, ISSN 0027-8424 Journal Code: 7505876

Contract/Grant No.: 45961; PHS Document type: Journal Article

Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

... lines the airway epithelium and creates a potential barrier to successful transfection of the epithelium in vivo. Based on the functional properties of pulmonary surfactant protein B (SP-B) and the fact that this protein is neither toxic nor immunogenic in the airway, we hypothesized that SP-B could be modified to deliver DNA to airway cells. We have modified native bovine SP-B by the covalent linkage of poly(lysine) (average molecular mass of 3.3 or 10...

... was determined by transfection of pulmonary adenocarcinoma cells (H441) in culture with the test plasmid pCPA-RSV followed by measurement of activity of the reporter gene encoding chloramphenicol acetyltransferase (CAT). Transfections were performed with DNA . protein complexes using poly(lysine)10kDa-SP-B ([Lys]10kDa-SP-B) or poly(lysine)3.3kDa-SP-B ([Lys]3.3kDa-SP-B), and results were compared with transfections using unmodified poly(lysine). DNA , unmodified SP-B. DNA , or DNA or DNA for [Lys]10kDa-SP-B.pCPA-RSV preparations, CAT activity was readily detectable the background of [Lys]3.3kDa-SP-B or unmodified SP-B. The SP-B-poly(lysine) conjugates were effective over a broad range of protein -to- DNA molar ratios, although they were optimal at approximately 500:1-1000:1. Transfection efficiency varied with the tested cell line but was not specific to...

... spectrometry (FTIR). Results of FTIR indicated that the conformation of [Lys]10kDa-SP-B was comprised primarily of alpha-helical structure compared with a predominantly aggregated structure of unmodified poly(lysine). We conclude that poly(lysine) conjugates of SP-B effectively deliver DNA in vitro and may have utility as DNA delivery vehicles to the airway in vivo.

Recombinant -- pharmacology -- PD; \*Drug DNA, Descriptors: --pharmacology--PD; \* Polylysine --pharmacology--PD; \*Proteolipids --pharmacology--PD; \*Pulmonary Surfactants--pharmacology--PD; \*Transfection --methods--MT

```
Chemical Name: DNA, Recombinant; Drug Carriers; Phosphatidylethanolamines
                                         Surfactants;
                                                          Polylysine
      Proteolipids;
                          Pulmonary
1,2-dielaidoylphosphatidylethanolamine; Chloramphenicol O-Acetyltransferase
                Description
Set
        Items
                (AGGREGATED OR MACROAGGREGATED) (S) (PROTEIN OR ANTIBODY OR
        15417
S1
             LIGAND OR ALBUMIN)
                S1 (S) (DNA OR VECTOR OR GENE OR (GENETIC (W) IMMUNIZATION-
         1278
S2
            ))
               S2 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENIMINE OR -
S3
            POLYIMMINE OR PEI)
               RD (unique items)
S4
                S2 AND (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR
S5
           11
            POLYIMMINE OR PEI)
S6
                RD S5 (unique items)
                S6 NOT S3
S7
?
S S1 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR POLYIMINES OR PEI)
           15417
            2730
                  POLYCATIONIC
                  POLYLYSINE
           10182
                  POLYETHELENEIMINE
                  POLYIMINES
            3958
                 S1 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE
      S8
                  OR POLYIMINES OR PEI)
?
RD S8
...completed examining records
              18 RD S8 (unique items)
?
S S9 AND (DNA OR VECTOR OR GENE)
              18
         2574560
                  DNA
          284815
                  VECTOR
         2492137
                 GENE
               3 S9 AND (DNA OR VECTOR OR GENE)
     S10
T S10/3,K/ALL
               (Item 1 from file: 155)
  10/3, K/1
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
           PMID: 12526712
12190474
  Novel shielded transferrin-polyethylene glycol-polyethylenimine/ DNA
  complexes for systemic tumor-targeted gene transfer.
  Kursa Malgorzata; Walker Greg F; Roessler Vanessa; Ogris Manfred; Roedl
Wolfgang; Kircheis Ralf; Wagner Ernst
                    Biology-Biotechnology,
                                              Department
                                                             for
                                                                   Pharmacy,
  Pharmaceutical
Ludwig-Maximilians-Universitaet, Butenandtstrasse 5-13, D-81377 Muenchen,
Germany.
  Bioconjugate chemistry (United States)
                                           Jan-Feb 2003, 14 (1) p222-31,
ISSN 1043-1802
                Journal Code: 9010319
  Document type: Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: Completed
  Novel shielded transferrin-polyethylene glycol-polyethylenimine/ DNA
  complexes for systemic tumor-targeted gene transfer.
  Tumor-targeting DNA complexes which can readily be generated by the
mixing of stable components and freeze-thawed would be very advantageous
```

for their subsequent application as medical products. Complexes were generated by the mixing of plasmid **DNA** , linear polyethylenimine (PEI22, 22 kDa) as the main **DNA** condensing agent, PEG- **PEI** (poly(ethylene glycol)-conjugated PEI ) for surface shielding, and Tf-PEG- PEI (transferrin-PEG- PEI ) to provide a ligand for receptor-mediated cell uptake. Within the shielding conjugates, PEG chains of varying size (5, 20, or 40 kDa) were conjugated with either linear PEI22 (22 kDa) or branched PEI25 (25 kDa). The three polymer components were mixed together at various ratios with DNA; particle size, surface charge, in vitro transfection activity, and systemic gene delivery to tumors was investigated. In general, increasing the proportion of shielding conjugate in the complex reduced surface charge, particle size, and in vitro transfection efficiency in transferrin receptor-rich K562 cells. The particle size or surface charge of the complexes containing the PEG- PEI conjugate did not significantly change after freeze-thawing, while complexes without the shielding conjugate aggregated . Complexes containing PEG- PEI conjugate efficiently transfected K562 cells after freeze-thawing. Furthermore the systemic application of freeze-thawed complexes exhibited in vivo tumor targeted expression. For complexes containing the luciferase reporter gene the highest expression was found in tumor tissue of mice. An optimum formulation for in vivo application, PEI22/Tf-PEG- PEI /PEI22-PEG5, encoding for the tumor necrosis factor containing plasmid DNA (TNF-alpha), inhibited tumor growth in three different murine tumor models. These new DNA complexes offer simplicity and convenience, with tumor targeting activity in vivo after freeze-thawing.

Descriptors: DNA --administration and dosage--AD; \*Drug Carriers --chemistry--CH; \* Gene Therapy; \*Neoplasms, Experimental--therapy--TH; Animals; DNA -- therapeutic use--TU; K562 Cells; Mice; Mice, Inbred Strains ; Molecular Weight; Polyethylene Glycols--chemistry--CH; Polyethyleneimine Transfection; Transferrin--chemistry--CH; --chemistry--CH; Outcome; Tumor...

Chemical Name: Drug Carriers; Polyethylene Glycols; Tumor Necrosis Factor ; Transferrin; Polyethyleneimine; DNA

(Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

PMID: 11741272 11586546

DNA /polyethylenimine transfection particles: influence of ligands, gene expression. polymer size, and PEGylation on internalization and

Ogris M; Steinlein P; Carotta S; Brunner S; Wagner E

of Biochemistry, University of Vienna, Vienna, Austria. Institute manfred.ogris@cup.uni-muenchen.de

AAPS pharmSci electronic resource (United States) 2001, 3 (3) pE21, Journal Code: 100897065 ISSN 1522-1059

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

DNA /polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression. into incorporated have been ligands Receptor-binding /polyethylenimine ( PEI ) complexes to enhance cell binding and cellular internalization. This study characterizes receptor-mediated uptake of DNA / PEI complexes on a cellular basis. A novel assay based on flow cytometry cell-associated total discriminating between applied, extracellularly bound DNA complexes. Receptor-mediated uptake of ligand -containing DNA / PEI (molecular weight, 800 kd) complexes was found to occur quickly (within 1 hour), whereas unspecific uptake through adsorptive endocytosis is less efficient or requires extended periods to reach the same degree of internalization. Rapid, receptor-mediated internalization requires a small complex size; however, large, aggregated complexes show higher gene expression. Using PEI 25 kd conjugated to large proteins such as transferrin or antibodies, improper condensation with DNA leads to suboptimal uptake and gene expression, whereas partial replacement of ligand - PEI with unconjugated OPEIO increases both uptake and transfection. In contrast, the 8 kd protein epidermal growth factor conjugated to PEI 25 kd properly condenses DNA and mediates specific uptake into human adenocarcinoma (KB) cells. Modification of the complex surface with appropriate amounts of poly(ethylene glycol) (PEG) does not block ligand -mediated internalization. A higher degree of PEGylation reduces the internalization of transferrin or antibody -containing complexes to a level similar to that of ligand -free complexes. In contrast, epidermal growth factor "mediated uptake is less effected by excessive PEGylation.

Descriptors: DNA --chemistry--CH; \* Gene Transfer Techniques;
\*Polyethylene Glycols--chemistry--CH; \*Polyethyleneimine; DNA --metabolism
--ME; Drug Carriers; Endocytosis; Epidermal Growth Factor--chemistry--CH;
Flow Cytometry; Genes, Reporter; Jurkat Cells; KB Cells; Ligands;
Luciferase--genetics--GE; Luciferase--metabolism--ME...
Chemical Name: Drug Carriers; Ligands; Muromonab-CD3; Plasmids;
Polyethylene Glycols; Transferrin; Epidermal Growth Factor;
Polyethyleneimine; DNA; Luciferase

10/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11347280 PMID: 11437332

A small, synthetic peptide for gene delivery via the serpin-enzyme complex receptor.

Patel S; Zhang X; Collins L; Fabre J W

Department of Clinical Sciences, Guy's, King's and St Thomas' School of Medicine, King's College Hospital, London, UK.

journal of gene medicine (England) May-Jun 2001, 3 (3) p271-9,

ISSN 1099-498X Journal Code: 9815764

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

# A small, synthetic peptide for gene delivery via the serpin-enzyme complex receptor.

BACKGROUND: The serpin-enzyme complex receptor (SECR) has previously been successfully targeted for gene delivery using synthetic peptide ligands covalently linked in fluid phase to commercially available polylysine preparations (approximately 10-54kDa). The objective of the present study was to improve this approach by the use of small, bifunctional, and easily standardised synthetic peptides. METHODS: Two synthetic peptides designated (K16 FNKPFVFLI) and PAT2 (K16 1 (PAT1) polylysine antitrypsin CSIPPEVKFNKPFVFLI) were evaluated for gene delivery to the HUH7 human hepatocyte cell line. The K16 moiety binds DNA electrostatically, while the FVFLM motif of human alphal-antitrypsin targets the SECR. RESULTS: Both PAT1 and PAT2 bind to and condense DNA into small particles as shown by laser scattering techniques. However, only PAT2 is effective for gene delivery, presumably on account of the greater distance between the K16 chain and the FVFLM motif. Gene delivery by PAT2/ DNA complexes is chloroquine-dependent, can be blocked completely by free ligand (CSIPPEVKFNKPFVFLI), and is highly efficient (e.g. approximately five-fold more effective than lipofectamine). At physiological salt concentrations, PAT2/ DNA complexes formed at 4 microg/ml DNA are approximately 350 nm in diameter and highly effective for gene transfer, but at 100 microg/ml DNA the complexes are aggregated (diameter > 4 microm) and inactive. CONCLUSIONS: A small (33 amino acid), bifunctional, synthetic peptide

```
represents a highly efficient and readily standardised DNA
                                                                vector for
the SECR. The effectiveness of this peptide depends on the distance of the
K16 moiety from the targeting ligand . High salt concentrations are not
                                            complexes.
required to form effective vector
                                      DNA
                        Transfer Techniques; *Receptors, Cell Surface
 Descriptors:
                 Gene
--metabolism--ME
        Items
                Description
Set
                (AGGREGATED OR MACROAGGREGATED) (S) (PROTEIN OR ANTIBODY OR
S1
        15417
              LIGAND OR ALBUMIN)
                S1 (S) (DNA OR VECTOR OR GENE OR (GENETIC (W) IMMUNIZATION-
         1278
S2
             ))
                S2 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENIMINE OR -
S3
             POLYIMMINE OR PEI)
                RD (unique items)
            3
S4
                S2 AND (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR
S_5
           11
             POLYIMMINE OR PEI)
                RD S5 (unique items)
            5
S6
            2
                S6 NOT S3
S7
                S1 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR
           36
S8
             POLYIMINES OR PEI)
                RD S8 (unique items)
           18
59
                S9 AND (DNA OR VECTOR OR GENE)
            3
S10
S (AB-PEI-DNA) OR (AB-PEI-VECTOR)
                  AB-PEI-DNA
               0
                  AB-PEI-VECTOR
                0
                  (AB-PEI-DNA) OR (AB-PEI-VECTOR)
                0
     S11
?
  (EXPRESSION (W) LIBRARY (W) IMMUNIZATION)
         2265064 EXPRESSION
          143284 LIBRARY
           202627 IMMUNIZATION
                  (EXPRESSION (W) LIBRARY (W) IMMUNIZATION)
               71
     S12
?
S S12 AND S1
               71
                   S12
            15417
                   S1
                   S12 AND S1
                0
     S13
?
S S12 AND REVIEW
                   S12
               71
          1737797
                  REVIEW
                  S12 AND REVIEW
                5
      S14
 ?
 RD
 ...completed examining records
                4 RD (unique items)
      S15
 T S15/3,K/ALL
                (Item 1 from file: 5)
   15/3, K/1
                 5:Biosis Previews(R)
 DIALOG(R)File
 (c) 2004 BIOSIS. All rts. reserv.
              BIOSIS NO.: 200400295729
 0014924972
                        immunization to discover and improve vaccine
               library
  Expression
  antigens
 AUTHOR: Barry Michael A (Reprint); Howell Dasein P G; Andersson Helen A;
   Chen Jiang Li; Singh Rana A K
 AUTHOR ADDRESS: Ctr Cell and Gene Therapy, Baylor Coll Med, 1 Baylor
   Plaza, BCM505, Houston, TX, 77030, USA**USA
 AUTHOR E-MAIL ADDRESS: mab@bcm.tmc.edu
 JOURNAL: Immunological Reviews 199 (1): p68-83 June 2004 2004
```

```
MEDIUM: print
ISSN: 0105-2896
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Citation
LANGUAGE: English
                        immunization to discover and improve vaccine
              library
 Expression
 antigens
DESCRIPTORS:
                                              immunization --
  METHODS & EQUIPMENT: expression
                                    library
  MISCELLANEOUS TERMS: ...Literature Review
               (Item 1 from file: 73)
  15/3,K/2
DIALOG(R) File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.
             EMBASE No: 2003331777
12221990
  Advances in the identification and characterization of protective
 antigens for recombinant vaccines against tick infestations
  De la Fuente J.; Kocan K.M.
  J. De la Fuente, Dept. of Veterinary Pathobiology, College of Veterinary
  Medicine, Oklahoma State University, Stillwater, OK 74078 United States
  AUTHOR EMAIL: jose delafuente@yahoo.com
  Expert Review of Vaccines ( EXPERT REV. VACCINES ) (United Kingdom)
  2003, 2/4 (583-593)
                 ISSN: 1476-0584
  CODEN: ERVXA
  DOCUMENT TYPE: Journal ; Review
                      SUMMARY LANGUAGE: ENGLISH
  LANGUAGE: ENGLISH
  NUMBER OF REFERENCES: 77
   ...identified and characterized, discovery of new antigens remains the
limiting step for improving the efficacy of tick vaccines. Recent
technologies developed for gene discovery, including expression
  immunization and evaluation of expressed sequence tags, show promise for
rapid, systematic and global antigen screening and should provide a
comprehensive approach to selection of candidate...
MEDICAL DESCRIPTORS:
drug synthesis; ectoparasite; mosquito; pathogenesis; infection control;
drug determination; drug efficacy; treatment outcome; immunization; disease
transmission; drug formulation; vaccination; human; clinical trial; review
; priority journal
                (Item 2 from file: 73)
  15/3, K/3
DIALOG(R)File 73:EMBASE
 (c) 2004 Elsevier Science B.V. All rts. reserv.
             EMBASE No: 2003151720
12040256
  Enhanced efficacy of DNA vaccines against an intracellular bacterial
 pathogen by genetic adjuvants
  Leclercq S.; Harms J.S.; Oliveira S.C.
  S.C. Oliveira, Department of Biochem./Immunology, Federal University of
  Minas Gerais, Inst. for Investigation Immunology, Av Antonio Carlos 6627,
  Belo Horizonte-MG 30161-970 Brazil
  AUTHOR EMAIL: scozeus@icb.ufmg.br
  Current Pharmaceutical Biotechnology ( CURR. PHARM. BIOTECHNOL. ) (
                2003, 4/2 (99-107)
  Netherlands)
                ISSN: 1389-2010
  CODEN: CPBUB
  DOCUMENT TYPE: Journal ; Review
                     SUMMARY LANGUAGE: ENGLISH
  LANGUAGE: ENGLISH
  NUMBER OF REFERENCES: 97
   ...immunogens. Secondly, we reported the use of cytokine genes and
 genetic adjuvants that could improve the immunogenicity of target genes.
```

```
And finally, we discussed the " Expression
                                               Library
                                                         Immunization
strategy and the recent results obtained against Brucella abortus
infection.
MEDICAL DESCRIPTORS:
...bacterial virulence; DNA hybridization; cytokine production; cytotoxic T
lymphocyte; muscle necrosis; muscle regeneration; immunostimulation;
antigen presenting cell; drug potentiation; gene construct; CpG island;
nonhuman; mouse; review
  15/3,K/4
                (Item 3 from file: 73)
DIALOG(R)File
               73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.
             EMBASE No: 1998327856
07436928
 DNA vaccines
  Lai W.C.; Bennett M.
  Dr. W.C. Lai, Department of Pathology, Texas Univ. Southwestern Med. Ctr., 5323 Harry Hines Blvd., Dallas, TX 75235-9072 United States
  Critical Reviews in Immunology ( CRIT. REV. IMMUNOL. ) (United States)
  1998, 18/5 (449-484)
                 ISSN: 1040-8401
  CODEN: CCRID
  DOCUMENT TYPE: Journal; Review
                      SUMMARY LANGUAGE: ENGLISH
  LANGUAGE: ENGLISH
  NUMBER OF REFERENCES: 235
  ...induction of injury to muscles prior to injection of DNA to enhance
gene expression. Vaccination performed using DNA without knowing beforehand
the protective epitopes, using 'expression library immunization ', is
discussed. While this field is bound to expand rapidly for future clinical
applications, we try to point out potential pitfalls as well as advantages
MEDICAL DESCRIPTORS:
protein expression; helper cell; aerosol; gene expression; dna library;
antigen presenting cell; dendritic cell; immune response; drug effect;
cloning vector; nonhuman; mouse; rat; animal cell; review ; priority
journal
Set
        Items
                 Description
                 (AGGREGATED OR MACROAGGREGATED) (S) (PROTEIN OR ANTIBODY OR
S1
        15417
              LIGAND OR ALBUMIN)
                 S1 (S) (DNA OR VECTOR OR GENE OR (GENETIC (W) IMMUNIZATION-
S2
         1278
              ))
                 S2 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENIMINE OR -
53
             POLYIMMINE OR PEI)
                 RD (unique items)
S4
                 S2 AND (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR
S5
              POLYIMMINE OR PEI)
                 RD S5 (unique items)
56
             2
                 S6 NOT S3
S7
                 S1 (S) (POLYCATIONIC OR POLYLYSINE OR POLYETHELENEIMINE OR
            36
58
              POLYIMINES OR PEI)
                 RD S8 (unique items)
            18
S9
                 S9 AND (DNA OR VECTOR OR GENE)
             3
S10
                 (AB-PEI-DNA) OR (AB-PEI-VECTOR)
            0
S11
            71
                 (EXPRESSION (W) LIBRARY (W) IMMUNIZATION)
S12
S13
            0
                 S12 AND S1
               S12 AND REVIEW
             5
S14
             4 RD (unique items)
S15
?
COST
        06jul04 11:42:52 User259876 Session D646.2
                     0.971 DialUnits File155
```

\$1.68 8 Type(s) in Format 3 \$1.68 8 Types \$4.79 Estimated cost File155 \$0.75 0.256 DialUnits File159 \$0.75 Estimated cost File159 \$5.25 0.937 DialUnits File5 \$1.75 1 Type(s) in Format 3 \$1.75 1 Types \$7.00 Estimated cost File5 \$7.82 0.798 DialUnits File73 \$8.10 3 Type(s) in Format 3 \$8.10 3 Types Estimated cost File73 \$15.92 OneSearch, 4 files, 2.962 DialUnits FileOS \$4.25 INTERNET \$32.71 Estimated cost this search 3.140 DialUnits \$33.53 Estimated total session cost

### Return to logon page!

13 of 13